Optimising allopurinol therapy in the treatment of gout.

Completed

• Conditions: Gout; Inflammatory and Immune System - Other inflammatory or immune system disorders; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12611000743965
• Lead Sponsor: Richard Day

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Suffer from clinically diagnosed gout and commencing allopurinol therapy

Exclusion Criteria

Poor venous access for venepuncture.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To understand the dose-response relationship of allopurinol.[Plasma urate, creatinine and oxypurinol concentrations will be monitored after each dose escalation until the close of the study.];To achieve plasma urate concentrations lower than 0.30 mmol/L in patients with gout.[Allopurinol will be titrated upwards in patients with gout until plasma urate concentrations are lower than 0.30 mmol/L.]

Secondary Outcome Measures

Name	Time	Method
Determine what factors (dose, oxypurinol concentration, creatinine clearance, baseline plasma urate concentration) affect plasma urate concentrations achieved during treatment of allopurinol.[Factors that affect plasma urate concentrations of urate during allopurinol treatment will be determined after patients have reached plasma urate concentrations lower than 0.30 mmol/L.]